2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Durability of the Therapeutic Effect of Restorative Neurostimulation for Refractory Chronic Low Back Pain

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives

          The purpose of the ongoing follow‐up of ReActiv8‐A clinical trial is to document the longitudinal benefits of episodic stimulation of the dorsal ramus medial branch and consequent contraction of the lumbar multifidus in patients with refractory mechanical chronic low back pain (CLBP). We report the four‐year outcomes of this trial.

          Materials and Methods

          ReActiv8‐A is a prospective, single‐arm trial performed at nine sites in the United Kingdom, Belgium, and Australia. Eligible patients had disabling CLBP (low back pain Numeric Rating Scale [NRS] ≥6; Oswestry Disability Index [ODI] ≥25), no indications for spine surgery or spinal cord stimulation, and failed conventional management including at least physical therapy and medications for low back pain. Fourteen days postimplantation, stimulation parameters were programmed to elicit strong, smooth contractions of the multifidus, and participants were given instructions to activate the device for 30‐min stimulation‐sessions twice daily. Annual follow‐up through four years included collection of NRS, ODI, and European Quality of Life Score on Five Dimensions (EQ‐5D). Background on mechanisms, trial design, and one‐year outcomes were previously described.

          Results

          At baseline ( N = 53) (mean ± SD) age was 44 ± 10 years; duration of back pain was 14 ± 11 years, NRS was 6.8 ± 0.8, ODI 44.9 ± 10.1, and EQ‐5D 0.434 ± 0.185. Mean improvements from baseline were statistically significant ( p < 0.001) and clinically meaningful for all follow‐ups. Patients completing year 4 follow‐up, reported mean (±standard error of the mean) NRS: 3.2 ± 0.4, ODI: 23.0 ± 3.2, and EQ‐5D: 0.721 ± 0.035. Moreover, 73% of participants had a clinically meaningful improvement of ≥2 points on NRS, 76% of ≥10 points on ODI, and 62.5% had a clinically meaningful improvement in both NRS and ODI and 97% were (very) satisfied with treatment.

          Conclusions

          In participants with disabling intractable CLBP who receive long‐term restorative neurostimulation, treatment satisfaction remains high and improvements in pain, disability, and quality‐of‐life are clinically meaningful and durable through four years.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: found
          • Article: not found

          What low back pain is and why we need to pay attention

          Low back pain is a very common symptom. It occurs in high-income, middle-income, and low-income countries and all age groups from children to the elderly population. Globally, years lived with disability caused by low back pain increased by 54% between 1990 and 2015, mainly because of population increase and ageing, with the biggest increase seen in low-income and middle-income countries. Low back pain is now the leading cause of disability worldwide. For nearly all people with low back pain, it is not possible to identify a specific nociceptive cause. Only a small proportion of people have a well understood pathological cause-eg, a vertebral fracture, malignancy, or infection. People with physically demanding jobs, physical and mental comorbidities, smokers, and obese individuals are at greatest risk of reporting low back pain. Disabling low back pain is over-represented among people with low socioeconomic status. Most people with new episodes of low back pain recover quickly; however, recurrence is common and in a small proportion of people, low back pain becomes persistent and disabling. Initial high pain intensity, psychological distress, and accompanying pain at multiple body sites increases the risk of persistent disabling low back pain. Increasing evidence shows that central pain-modulating mechanisms and pain cognitions have important roles in the development of persistent disabling low back pain. Cost, health-care use, and disability from low back pain vary substantially between countries and are influenced by local culture and social systems, as well as by beliefs about cause and effect. Disability and costs attributed to low back pain are projected to increase in coming decades, in particular in low-income and middle-income countries, where health and other systems are often fragile and not equipped to cope with this growing burden. Intensified research efforts and global initiatives are clearly needed to address the burden of low back pain as a public health problem.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Non-specific low back pain.

            Non-specific low back pain affects people of all ages and is a leading contributor to disease burden worldwide. Management guidelines endorse triage to identify the rare cases of low back pain that are caused by medically serious pathology, and so require diagnostic work-up or specialist referral, or both. Because non-specific low back pain does not have a known pathoanatomical cause, treatment focuses on reducing pain and its consequences. Management consists of education and reassurance, analgesic medicines, non-pharmacological therapies, and timely review. The clinical course of low back pain is often favourable, thus many patients require little if any formal medical care. Two treatment strategies are currently used, a stepped approach beginning with more simple care that is progressed if the patient does not respond, and the use of simple risk prediction methods to individualise the amount and type of care provided. The overuse of imaging, opioids, and surgery remains a widespread problem.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The Oswestry Disability Index.

              The Oswestry Disability Index (ODI) has become one of the principal condition-specific outcome measures used in the management of spinal disorders. This review is based on publications using the ODI identified from the authors' personal databases, the Science Citation Index, and hand searches of Spine and current textbooks of spinal disorders. To review the versions of this instrument, document methods by which it has been validated, collate data from scores found in normal and back pain populations, provide curves for power calculations in studies using the ODI, and maintain the ODI as a gold standard outcome measure. It has now been 20 years since its original publication. More than 200 citations exist in the Science Citation Index. The authors have a large correspondence file relating to the ODI, that is cited in most of the large textbooks related to spinal disorders. All the published versions of the questionnaire were identified. A systematic review of this literature was made. The various reports of validation were collated and related to a version. Four versions of the ODI are available in English and nine in other languages. Some published versions contain misprints, and many omit the scoring system. At least 114 studies contain usable data. These data provide both validation and standards for other users and indicate the power of the instrument for detecting change in sample populations. The ODI remains a valid and vigorous measure and has been a worthwhile outcome measure. The process of using the ODI is reviewed and should be the subject of further research. The receiver operating characteristics should be explored in a population with higher self-report disabilities. The behavior of the instrument is incompletely understood, particularly in sensitivity to real change.
                Bookmark

                Author and article information

                Contributors
                seldabe@mac.com
                Journal
                Neuromodulation
                Neuromodulation
                10.1111/(ISSN)1525-1403
                NER
                Neuromodulation
                John Wiley & Sons, Inc. (Hoboken, USA )
                1094-7159
                1525-1403
                09 July 2021
                August 2021
                : 24
                : 6 ( doiID: 10.1111/ner.v24.6 )
                : 1024-1032
                Affiliations
                [ 1 ] Monash Clinical Research Pty Ltd Clayton VIC Australia
                [ 2 ] GZA Hospitals Wilrijk Belgium
                [ 3 ] Hunter Pain Clinic Broadmeadow NSW Australia
                [ 4 ] Sunshine Coast Clinical Research Noosa Heads QLD Australia
                [ 5 ] Pain Medicine of South Australia Welland SA Australia
                [ 6 ] The James Cook University Hospital Middlesbrough UK
                [ 7 ] Algemeen Ziekenhuis Nikolaas Sint‐Niklaas Belgium
                [ 8 ] St. Bartholomew's Hospital London UK
                [ 9 ] Leeds Teaching Hospitals NHS Trust Leeds UK
                [ 10 ] Brigham and Women's Healthcare Harvard Medical School Boston MA USA
                [ 11 ] Mainstay Medical BV Amsterdam The Netherlands
                Author notes
                [*] [* ] Address correspondence to: Sam Eldabe, The James Cook University Hospital, Marton Road, Middlesbrough TS4 3BW, UK. Email: seldabe@ 123456mac.com

                Author information
                https://orcid.org/0000-0001-7364-9917
                https://orcid.org/0000-0003-2937-827X
                https://orcid.org/0000-0002-1898-8243
                https://orcid.org/0000-0002-9250-1886
                Article
                NER13477
                10.1111/ner.13477
                8456956
                34242440
                cb1fb01e-e291-4eae-9b9f-6b50c0f5c5b0
                © 2021 The Authors. Neuromodulation: Technology at the Neural Interface published by Wiley Periodicals LLC on behalf of International Neuromodulation Society.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 27 April 2021
                : 25 January 2021
                : 18 May 2021
                Page count
                Figures: 3, Tables: 3, Pages: 9, Words: 6298
                Funding
                Funded by: Mainstay Medical Limited
                Categories
                Clinical Research
                PERIPHERAL NERVE STIMULATION
                Clinical Research
                Editor's Choice
                Custom metadata
                2.0
                August 2021
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.7 mode:remove_FC converted:22.09.2021

                chronic low back pain,long‐term effect,multifidus muscle impaired neuromuscular control,restorative neurostimulation

                Comments

                Comment on this article